<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="icon" type="image/svg+xml" href="favicon.svg">
    <meta name="description" content="Biotech Gainer Screening Methodology - SL Mar R&D Notes">
    <title>Biotech Gainer Screening Methodology | SL Mar</title>
    <link rel="stylesheet" href="styles.css">
    <style>
        .article-content {
            max-width: 900px;
            margin: 0 auto;
        }
        .article-content h1 {
            font-size: 2.5rem;
            margin-bottom: 1rem;
        }
        .article-content h2 {
            font-size: 1.75rem;
            margin-top: 2rem;
            margin-bottom: 1rem;
            padding-top: 1rem;
            border-top: 1px solid var(--border);
        }
        .article-content h3 {
            font-size: 1.25rem;
            margin-top: 1.5rem;
            margin-bottom: 0.75rem;
        }
        .article-content p {
            margin-bottom: 1rem;
            line-height: 1.8;
        }
        .article-content ul, .article-content ol {
            margin-left: 2rem;
            margin-bottom: 1rem;
        }
        .article-content li {
            margin-bottom: 0.5rem;
        }
        .article-content code {
            background: var(--bg-secondary);
            padding: 0.2rem 0.4rem;
            border-radius: 3px;
            font-size: 0.9em;
        }
        .article-content pre {
            background: var(--bg-secondary);
            padding: 1rem;
            border-radius: 6px;
            overflow-x: auto;
            margin-bottom: 1rem;
        }
        .article-content pre code {
            padding: 0;
            background: none;
        }
        .back-link {
            display: inline-block;
            margin-bottom: 2rem;
            color: var(--accent);
        }
    </style>
</head>
<body>
    <nav>
        <div class="container">
            <a href="index.html" class="logo">SL Mar - Maritime and AI Consultancy</a>
            <ul>
                <li><a href="index.html">Home</a></li>
                <li><a href="publications.html">Publications</a></li>
                <li><a href="development.html">Development</a></li>
                <li><a href="local-ai.html">Local AI</a></li>
                <li><a href="rnd-notes.html" class="active">R&D Notes</a></li>
                <li><a href="contact.html">Contact</a></li>
            </ul>
        </div>
    </nav>

    <section>
        <div class="container article-content">
            <a href="rnd-notes.html" class="back-link">← Back to R&D Notes</a>
            <h1>Biotech Gainer Screening Methodology</h1><p><strong>Analysis Date:</strong> October 2025</p><h2>Executive Summary</h2><p>Analysis of top biotech gainers reveals that <strong>most moves were speculative without specific catalysts</strong>, making them extremely difficult to predict with traditional fundamental screening. However, common technical patterns emerged that could be screened.</p><h2>Key Finding: Speculative Trading, Not News-Driven</h2><p><strong>CRITICAL INSIGHT:</strong> These massive gains occurred WITHOUT specific catalysts:
<li>❌ No FDA approvals announced</li>
<li>❌ No clinical trial data releases</li>
<li>❌ No partnership announcements</li>
<li>❌ No regulatory breakthroughs</li>
<li>✅ Speculative trading and sector momentum ONLY</li></ul><h2>Common Pre-Breakout Characteristics</h2><h3>1. Market Cap Profile</h3>
<li><strong>All were micro-caps</strong> (under $300M market cap)</li>
<li>Higher volatility and susceptibility to speculative rallies</li>
<li>Lower liquidity = easier to move on small volume</li></ul><h3>2. Volume Patterns (Predictive Factor)</h3>
<li><strong>5-day volume breakouts</strong> observed before the move</li>
<li><strong>SCREENING CRITERIA:</strong> Volume > 3x average (5-day vs 50-day)</li></ul><h3>3. Technical Indicators</h3>
<li><strong>RSI entering overbought territory (>70)</strong></li>
<li><strong>SCREENING CRITERIA:</strong> RSI 60-75 (momentum building, not yet exhausted)</li></ul><h3>4. Price Action Signals</h3>
<li><strong>Bullish chart patterns</strong> (W-bottoms, ascending triangles)</li>
<li><strong>Trend reversals</strong> from recent lows</li>
<li><strong>Breaking above moving averages</strong> (20/50-day)</li>
<li><strong>SCREENING CRITERIA:</strong> Price > 20-day MA AND 50-day MA</li></ul><h3>5. Sector Patterns</h3>
<li><strong>100% biotech/pharma sector concentration</strong></li>
<li>All stocks moved on <strong>sector momentum</strong>, not individual news</li></ul><h3>6. Pre-Market Activity (Day-Of Signal)</h3>
<li>Significant pre-market trading activity</li>
<li><strong>SCREENING CRITERIA:</strong> Pre-market volume > 50% of avg daily volume</li></ul><h2>Proposed Screening Methodology</h2><h3>Phase 1: Universe Selection</h3>
<li>Sector: Biotech / Pharmaceuticals</li>
<li>Market Cap: $50M - $500M (micro-cap focus)</li>
<li>Average Daily Volume: > 100K shares (minimum liquidity)</li>
<li>Exchange: NASDAQ/NYSE (no OTC)</li></ul><h3>Phase 2: Volume Breakout Detection</h3>
<li>Current Volume > 3x average volume (5-day vs 50-day)</li>
<li>OR: Volume spike in last 1-3 days (>200% vs avg)</li>
<li>Filter: Sustained volume (not single-day anomaly)</li></ul><h3>Phase 3: Technical Confirmation</h3>
<li>RSI(14): Between 60-75 (momentum building, not overbought)</li>
<li>Price Position: Above 20-day MA AND 50-day MA</li>
<li>Chart Pattern: Look for bullish patterns (manual or ML-based)</li></ul><h3>Phase 4: Pre-Market Monitoring (Day-Of)</h3>
<li>Pre-market volume > 50% of average daily volume</li>
<li>Pre-market price change > +5%</li></ul><h3>Phase 5: Risk Filters</h3>
<li>Exclude: Recent reverse splits (dilution risk)</li>
<li>Exclude: Bankruptcy filings or delisting warnings</li>
<li>Exclude: SEC investigations or fraud allegations</li></ul><h2>Implementation Strategy</h2><h3>Combined Approach (Recommended)</h3>
<li><strong>Evening Screener:</strong> Generate watchlist of 10-20 candidates</li>
<li><strong>Manual Review:</strong> Check for chart patterns, recent news</li>
<li><strong>Pre-Market Filter:</strong> Only trade those showing pre-market momentum</li>
<li><strong>Entry Strategy:</strong> Wait for first 30-min, enter on pullback or breakout confirmation</li></ul><h2>Critical Limitations</h2><h3>1. Speculative Nature</h3>
<li><strong>Most moves had NO fundamental catalyst</strong></li>
<li>Impossible to predict which micro-cap will get speculative interest</li>
<li>High false positive rate (many setups fail)</li></ul><h3>2. Risk Management Essential</h3>
<li><strong>Stop Loss:</strong> 10-15% maximum per position</li>
<li><strong>Position Size:</strong> 0.5-1% of portfolio per trade</li>
<li><strong>Exit Strategy:</strong> Take profits quickly (these moves fade fast)</li></ul><h3>3. Low Repeatability</h3>
<li>Speculative rallies are <strong>not sustainable</strong></li>
<li>Many gainers reverse 50%+ within days</li>
<li>Focus on <strong>momentum capture</strong>, not hold-and-hope</li></ul><h2>Conclusion</h2><p><strong>Biotech gainers are driven by speculative momentum, not news catalysts.</strong> While common technical patterns exist (volume breakouts, RSI momentum, micro-cap profile), predicting WHICH stock will explode is extremely difficult.</p><p><strong>Success requires:</strong>
<li>High volume of candidates (cast wide net)</li>
<li>Strict risk management (small position sizes, tight stops)</li>
<li>Quick profit-taking (momentum fades fast)</li>
<li>Acceptance of low hit rate (~40-60%) offset by large wins</li></ul><p><strong>This is NOT a "set and forget" strategy.</strong> It requires active monitoring, fast execution, and comfort with high volatility.
</p>
        </div>
    </section>

    <footer>
        <div class="container">
            <p>&copy; 2025 SL Mar</p>
            <p>AI for Quantitative Finance and Maritime Applications</p>
            <p>France • SIRET 98770400400017</p>
        </div>
    </footer>
</body>
</html>